Synonym
Morniflumate; UP-164; UP 164; UP164; Morniflu; Niflam
IUPAC/Chemical Name
2-morpholinoethyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate
InChi Key
LDXSPUSKBDTEKA-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)
SMILES Code
O=C(OCCN1CCOCC1)C2=C(NC3=CC=CC(C(F)(F)F)=C3)N=CC=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Morniflumate (UP 164) is an orally active nonsteroidal anti-inflammatory agent.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
125.0 |
316.15 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
395.38
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Cremonesi G, Cavalieri L. Efficacy and safety of morniflumate for the treatment of symptoms associated with soft tissue inflammation. J Int Med Res. 2015 Jun;43(3):290-302. doi: 10.1177/0300060514567212. Epub 2015 Apr 28. Review. PubMed PMID: 25921871.
2: Cho HY, Park GK, Lee YB. Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by high-performance liquid chromatography in stability and pharmacokinetic studies. Biomed Chromatogr. 2013 Nov;27(11):1438-43. doi: 10.1002/bmc.2940. Epub 2013 May 30. PubMed PMID: 23722315.
3: Mero F, Nettis E, Aloia AM, Di Leo E, Ferrannini A, Vacca A. Short-term tolerability of morniflumate in patients with cutaneous hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):247-50. PubMed PMID: 23527729.
4: Civelli M, Vigano T, Acerbi D, Caruso P, Giossi M, Bongrani S, Folco GC. Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9. PubMed PMID: 1659152.
5: Manach Y, Ditisheim A. Double-blind, placebo-controlled multicentre trial of the efficacy and tolerance of morniflumate suppositories in the treatment of tonsillitis in children. J Int Med Res. 1990 Jan-Feb;18(1):30-6. Erratum in: J Int Med Res 1990 Mar-Apr;18(2):preceding 75. PubMed PMID: 2110537.
6: Marchioni CF, Livi E, Oliani C, Guerzoni P, Corona M. [Treatment of acute inflammatory pathology of the upper airway with morniflumate]. Riv Eur Sci Med Farmacol. 1990 Dec;12(6):347-57. Italian. PubMed PMID: 2132289.
7: Schiantarelli P, Cadel S, Folco GC. Gastroprotective effects of morniflumate, an esterified anti-inflammatory drug. Arzneimittelforschung. 1984;34(8):885-90. PubMed PMID: 6333880.
8: Melica A, Donateo L, Gerardi R, Parenti M. [A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis]. Riv Eur Sci Med Farmacol. 1991 Feb-Apr;13(1-2):51-60. Italian. PubMed PMID: 1796197.
9: Schiantarelli P, Cadel S, Acerbi D. A gastroprotective anti-inflammatory agent: the beta-morpholinoethyl ester of niflumic acid (morniflumate). Agents Actions. 1984 Feb;14(2):247-56. PubMed PMID: 6608862.
10: Portmann M, Portmann D, Rohou S, Pollet M, Colson J, Cuvelier A, Fournier JL, Jeannerot F, Marx J, Menet V. [Efficacy and tolerability of morniflumate in acute otitis in infants: results of a randomized study versus placebos]. Rev Laryngol Otol Rhinol (Bord). 1990;111(5):507-10. French. PubMed PMID: 2087618.
